Trial · NCT06998940
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940, Phase 3, Recruiting, SWOG Cancer Research Network
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations. Trials, record NCT06998940. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06998940
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- NCT number
- NCT06998940
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 94 participants, estimated
- Lead sponsor
- SWOG Cancer Research Network
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration
- First posted
- 2025-05-31
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | From date of randomization to date of death due to any cause, assessed up to 3 years | Analysis of OS will be conducted in all eligible participants according to the intent-to-treat principle using a 1-sided stratified log rank test. |
| Secondary | Objective response rate (ORR) | Up to 3 years after randomization | Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be compared across treatment arms via Fisher's exact test. |
| Secondary | Disease control rate | Up to 3 years after randomization | Will be compared across treatment arms via Fisher's exact test. |
| Secondary | Duration of response (DoR) | Up to 3 years after randomization | The distributions of DoR will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
| Secondary | Progression free survival (PFS) | From date of randomization to date of first documentation of progression or symptomatic deterioration (per RECIST 1.1), or death due to any cause, up to 3 years | The distributions of PFS will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
| Secondary | Incidence of adverse events | Up to 30 days after last study treatment | |
| Secondary | OS in participants with MAPK negative cancers | From date of randomization to date of death due to any cause, assessed up to 3 years | The distributions of OS will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
| Secondary | PFS in participants with MAPK negative cancers | From date of randomization to date of first documentation of progression or symptomatic deterioration (per RECIST 1.1), or death due to any cause, up to 3 years | The distributions of PFS will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
| Secondary | ORR in participants with MAPK negative cancers | Up to 3 years after randomization | Will be compared across treatment arms via Fisher's exact test. |
| Other | Health-related quality of life (QOL) | At 8 weeks after randomization | Measured by the Functional Assessment of Cancer Therapy - General (FACT-G) total score. Analysis will be conducted using multiple linear regression analysis, adjusting for the clinical study-specified stratification factors (which are also anticipated to influence QOL endpoints), and the baseline score as covariates. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA180888 | SWOG Network Group Operations Center of the NCTN | LARA, PRIMO N.; HERSHMAN, DAWN | UNIVERSITY OF CALIFORNIA AT DAVIS | NATIONAL CANCER INSTITUTE | 2014 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06998940
GET https://conductscience.org/api/trials/v1/NCT06998940/registered